First human tests for new Alzheimer's pill halted
NCT ID NCT07016464
Summary
This was an early-stage study to check the safety of a new oral medicine called REM0045392, which is being developed to treat Alzheimer's disease. It involved 19 healthy men and older adults who took single or multiple doses over 14 days. The main goal was to see how the body processes the drug, if it's well-tolerated, and whether taking it with food makes a difference.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium NV - Clinical Pharmacology Unit
Edegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.